Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
25 Mayo 2023 - 7:00AM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for idiopathic Pediatric
Growth Hormone Deficiency (iPGHD) through Phase 2 clinical trials,
announced today that interim data from its OraGrowtH210 and
OraGrowtH212 Trials will be reviewed in two oral presentations in
Session OR21 – “Update on Growth Disorders” at the 2023 Annual
Meeting of the Endocrine Society (ENDO), held in Chicago, Illinois,
June 15-18, 2023. Lumos Pharma will host a virtual Key Opinion
Leader (KOL) Webinar on June 21, 2023, 11:00 AM – 12 PM EDT where
Drs. Fernando Cassorla and Michael Tansey will review interim data
evaluating oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD
OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the
ENDO Meeting.
ENDO Session OR21 – Update on Growth
Disorders – Saturday, June 17, 2023, 3:30 – 5:00 PM
CDT
- Title (Abstract
6273) – Dose Responsiveness of LUM-201 as Measured by Acute
GH Response and IGF-1 and Annualized Height Velocity (AHV) Measured
at 6 Months in the Interim Analysis of the OraGrowtH212 Study in
Idiopathic Pediatric Growth Hormone Deficiency
(iPGHD), Fernando Cassorla, MD, Chief of
Pediatric Endocrinology, University of Chile
- Title (Abstract
6014) – Growth Response of Oral LUM-201 in OraGrowtH210 and
OraGrowtH212 Trials in Idiopathic Pediatric Growth Hormone
Deficiency (iPGHD): Combined Analysis Interim Analysis
Data, Michael Tansey, MD, Clinical
Professor of Pediatrics-Endocrinology and Diabetes, University of
Iowa, Carver College of Medicine
Virtual KOL Webinar – Wednesday, June 21, 2023, 11:00 AM
– 12:00 PM EDT
- To register for the virtual KOL Event, please click through the
link HERE
The event will feature presentations by KOLs in the field of
pediatric endocrinology, Fernando Cassorla, MD, Chief of Pediatric
Endocrinology, University of Chile, and Michael Tansey, MD,
Clinical Professor of Pediatrics-Endocrinology and Diabetes,
University of Iowa, Carver College of Medicine who will review
interim data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials
presented at ENDO. Drs. Cassorla and Tansey will be available to
answer questions following their formal presentations.
KOL Biographies
Fernando Cassorla, M.D. is currently Chief of
Pediatric Endocrinology at the Institute of Maternal and Child
Research of the University of Chile, a position he has held since
1993. Previously, beginning in 1979 Dr. Cassorla served as Senior
Investigator at the Developmental Endocrinology Branch of the
National Institute of Child Health and Human Development, rising to
the position of Clinical Director of this Institute in 1990. He has
authored numerous chapters in pediatric endocrinology, authored or
co-authored over 200 original articles in peer reviewed journals,
and has presented over 300 abstracts at scientific meetings. Dr.
Cassorla received his MD from the University of Chile. He is Board
Certified in both Pediatrics and Pediatric Endocrinology, having
completed his pediatric residency at the Albany Medical Center in
New York and his fellowship in Pediatric Endocrinology at the
Children´s Hospital of Philadelphia. Dr. Cassorla has received
several international awards for his work and was elected to the
Chilean Academy of Medicine for a lifetime position in 2003.
Michael Tansey, M.D. is currently Clinical
Professor, Department of Pediatrics, Division of Pediatric
Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, a
position he has held since 2012, having first served as Clinical
Assistant Professor there 2001-2006, then as Clinical Associate
Professor 2006-2012. Dr. Tansey also currently serves as Clinical
Director for Division of Pediatric Endocrinology and Diabetes,
Department of Pediatrics, University of Iowa. He has been a
co-investigator for one of the 5 clinical centers for the NIH
funded Diabetes Research in Children Network “DirecNet” group since
2001 and has co-authored numerous peer-reviewed scientific
publications on brain function and growth in children with Type 1
diabetes. Dr. Tansey received his MD from Loyola Stritch School of
Medicine, Maywood, Illinois, and completed his residency in
pediatrics and his fellowship in pediatric endocrinology at the
University of Iowa Children’s Hospital and University of Iowa
Hospitals and Clinics, respectively. He has received several awards
including the Riesz Award, University of Iowa, and the Mary Tyler
Moore and S. Robert Levine, MD, Excellence in Clinical Research
Award.
About Pediatric Growth Hormone Deficiency and
LUM-201
Pediatric Growth Hormone (GH) Deficiency is the consequence of
inadequate secretion of growth hormone from the pituitary gland in
children resulting in low GH in the body, insufficient production
of downstream signaling molecules required for growth, and the
subsequent lack of growth. LUM-201, also known as ibutamoren, is an
orally administered investigational small molecule that promotes
the secretion of GH from the pituitary gland and represents an
opportunity for appropriately selected patients to avoid the daily
or weekly injections involved with current or forthcoming
therapies. LUM-201 has been observed to increase the amplitude of
endogenous pulsatile GH secretion, which mimics the natural pattern
of GH secretion.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos Pharma
was founded and is led by a management team with longstanding
experience in rare disease drug development. Lumos Pharma’s lead
therapeutic candidate is LUM-201, an oral growth hormone
stimulating small molecule, currently being evaluated in several
Phase 2 clinical trials for the treatment of idiopathic Pediatric
Growth Hormone Deficiency (iPGHD): the dose-finding OraGrowtH210
Trial; the PK/PD mechanistic OraGrowtH212 Trial; and a switch
trial, the OraGrowtH213 Trial. If approved by the FDA, LUM-201
would provide an orally administered alternative to recombinant
growth hormone injections that PGHD subjects otherwise endure for
many years of treatment. LUM-201 has received Orphan Drug
Designation in both the US and EU. For more information, please
visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024